Cory Dobson, Author at Sanford Burnham Prebys - Page 3 of 41

Author: Cory Dobson

Institute News

How cancer research silos perpetuate inequity in cancer outcomes: An interview with Svasti Haricharan

AuthorMiles Martin
Date

April 18, 2023

Svasti Haricharan, PhD

The National Institutes of Health recognizes National Minority Health Month each April. This is a time to raise awareness about the importance of reducing the health disparities faced by racial and ethnic minorities.

For our part, we spoke to Assistant Professor Svasti Haricharan, PhD, about her recently published review in Clinical Cancer Research. The paper describes some of the shortfalls of the current research focusing on cancer disparities. It also reveals what needs to happen to solve this problem. 

This paper describes “research silos” in cancer disparities, but what does this term mean?
The cancer research community has made a lot of progress recognizing that cancer research has a data diversity problem. We know that we need more researchers working on cancer disparities—for example, finding explanations as to why some racial and ethnic minorities have worse cancer survival rates than others. We also know that we need to generate more inclusive data in cancer research generally, which means building databases that include data from people of different backgrounds.

However, what we’re talking about in this new paper is a bit more subtle than that. It has more to do with which disparities researchers are studying and how they’re studying them. Cancer-disparities researchers tend to fall into two different categories with two very different approaches. One group focuses more on the societal problems driving disparities, and the other group is looking closely at the biology. But these two paths aren’t intersecting, which is preventing us from truly addressing racial disparities in cancer.

Can you tell us more about those two groups and how this division affects cancer research?
The first group includes researchers who study cancer disparities in the way most people understand them. They focus on social determinants of health, such as socioeconomic status and systemic bias in the healthcare system. The second group looks at the biology directly, focusing on how genetics impacts the molecular biology of cancer. These are both important research areas, and we’ve made a lot of progress independently with each of them.

The problem is that focusing on one or the other ignores something critical that has gained attention in recent years: lifestyle factors have a direct impact on the molecular biology of cancer. Our lived experiences leave a unique footprint in our cells on top of what’s already there because of what we inherited at birth. By keeping these two types of cancer research trapped in silos, we’re missing synergistic leaps that could truly transform our understanding of cancer outcome inequity. Breaking down these silos is the only way to keep moving this type of research forward.

How can we break down these silos? 
Looking at it broadly, funding bodies need to invest more in research that develops datasets using biological samples from underrepresented groups. This will help us learn more about how societal factors can have a different impact on the biology of cancer—depending on the person with the disease. Here in the lab, we need to create experimental systems that better represent the biology of people from racial and ethnic minorities. This could also help us solve an even bigger problem.

Therapeutic strategies for cancer that we find in the lab don’t often make it to the clinic. Improving the diversity of our cancer data will improve this success-to-failure ratio. It will help us identify treatments that work better in some people than in others and choose the best treatments for each patient. In other words, it will help us work toward truly individualized medicine. Ultimately, we can only develop good precision medicine for cancer when we start looking at all patient demographics more equitably.

Institute News

Erkki Ruoslahti named a Fellow of the AACR Academy

AuthorMiles Martin
Date

April 14, 2023

Erkki Ruoslahti, MD PhD

The American Association for Cancer Research (AACR) has elected Distinguished Professor Emeritus Erkki Ruoslahti, MD PhD, to its 2023 class of Fellows of the AACR Academy. The mission of the AACR Academy is to recognize and honor distinguished scientists whose scientific contributions have propelled significant innovation and progress against cancer.

Fellows of the AACR Academy serve as a global brain trust of top contributors to cancer science and medicine who help advance the mission of the AACR to prevent and cure all cancers through research, education, communication, collaboration, science policy and advocacy, and funding for cancer research.

All Fellows are nominated and elected through an annual, multi-step peer review process that involves a rigorous assessment of each candidate’s scientific accomplishments in cancer research and cancer-related sciences. Only individuals whose work has had a significant and enduring impact on cancer research are considered for election and induction into the AACR Academy.

“We are proud to announce the election of 23 new Fellows of the AACR Academy. These individuals from across the world have all made significant and groundbreaking contributions to cancer research,” said Margaret Foti, Ph.D, M.D (hc), chief executive officer of the AACR. “The 2023 class of Fellows includes pioneers from numerous scientific disciplines who have collectively shaped our understanding and treatment of cancer. We are deeply honored to have them join our 289 existing Fellows and look forward to celebrating their extraordinary scientific achievements at our upcoming Annual Meeting.”

Erkki Ruoslahti, MD, PhD

Ruoslahti was elected for his paramount discoveries involving the mechanisms of cellular adhesion; for the co-discovery of fibronectin, the discovery of the fibronectin RGD cell attachment sequence, homing peptides, and tumor-penetrating peptides; and for the development of therapeutics for vascular thrombosis and cancer.

Ruoslahti joined Sanford Burnham Prebys in 1979 and served as its President from 1989-2002. In 2022, Ruoslahti announced as one of three winners of the Albert Lasker Basic Medical Research Award for his work on cellular adhesion. Ruoslahti’s other honors include the Japan Prize, the Gairdner Foundation International Award, the G.H.A. Clowes Memorial Award, and the Robert J. and Claire Pasarow Foundation Medical Research Award. He is a Knight of the Order of the White Rose of Finland, a Commander of the Order of the Lion of Finland, and one of the most cited scientists in the world.

This post was adapted from a press release issued by the American Association for Cancer Research.

Institute News

Behind the scenes at Sanford Burnham Prebys’ Cancer Center

AuthorMiles Martin
Date

March 28, 2023

A scientist - a young woman with glasses - presents her poster on colorectal cancer to a group of interested open house guests

Cancer Center open house connects San Diego community with scientists working toward cancer cures

The Institute’s NCI-designated Cancer Center hosted an open house to showcase the latest research advances in cancers of the digestive system. The event was sponsored by the center’s Community Advisory Board (CAB), which provides a link to community networks of people—including patients, survivors and their loved ones.

“These events are especially helpful for people affected by cancer because our researchers can explain the science behind the disease and the approaches we use to find new treatments,” says Associate Professor Cosimo Commisso, PhD, who co-hosted the event with Adjunct Associate Professor Pamela Itkin-Ansari, PhD “As researchers, it’s critical that we have community participation to influence our research—so we benefit as well.” 

The open house, which was free to the public, fulfills a key part of the CAB’s mission—to create awareness of the cancer research being done at the Institute and to promote dialogue between its scientists and the community. Guests had the chance to mingle with cancer researchers, and there was also a panelist table, where they could ask questions directly to a panel including two cancer survivors and a clinician.

The theme of the open house was cancers of the digestive system, which includes pancreatic cancer, liver cancer, stomach cancer and colorectal cancer. Although these cancers are very diverse, one thing many cancers of the digestive system have in common is that they take a long time to diagnose and are difficult to treat. 

“These are devastating cancers,” says Commisso. “We’ve doubled the survival rates for pancreatic cancer since I started working in this field over a decade ago, but it’s still only around 10%. And that’s just not good enough.”

Attendees also got behind-the-scenes tours of labs, including Commisso’s, where researchers are working to halt pancreatic cancer by blocking nutrients—in essence, starving tumor cells of the fuel they need to grow and proliferate. 

“We have a lot of researchers taking different approaches to cancer here at the Institute, and it’s important for people affected by cancer to know that while we’re still a long way off from ending cancer forever, we’re still making progress,” adds Commisso.

Institute News

Padres Pedal the Cause 2023: Team Sanford Burnham Prebys raises $50,000 for cancer research

AuthorMiles Martin
Date

March 20, 2023

Group photo of Team Sanford Burnham Prebys 2023

Team Sanford Burnham Prebys hit the pavement this weekend for Padres Pedal the Cause, an annual fundraising event that invites participants to cycle, spin, run or walk to support local cancer research. The funds raised through each year’s race go to seed grants that fund collaborative cancer research projects in San Diego. 

“Padres Pedal the Cause is a chance for the cancer community to come together and remember why collaboration is so important in cancer research,” says bike rider Ze’ev Ronai, PhD, director of the Institute’s NCI-designated Cancer Center. “Virtually all of us know somebody who has been impacted by cancer, including me. This is my fifth Padres Pedal the Cause, and every year I’m so proud to be part of our Institute’s team and help contribute to cancer research outside the lab.”

This year’s team was formidable: 56 employees and friends of the Institute signed up to either ride, run, or walk in the event. Team members came from all areas of the Institute, including faculty, staff scientists, administrative staff, postdocs, and even current and former members of the Institute’s Board of Trustees, such as Bill Gerhart and Steve Williams. Other notable names on this year’s team included longtime participants such as Professor Nicholas Cosford, PhD and James Short, associate director of Digital Communications and Design. 

“I’ve been with Padres Pedal the Cause since the very beginning, and it’s one of the highlights of my year,” says Short, who has helped lead the Institute’s team for the last 10 years.

The team also included some new members this year, such as Assistant Professor Lukas Chavez, PhD, and Director of Experimental Pharmacology Raghu Ramachandra, PhD, who both joined the Institute late last year. 

While Institute employees were well represented on this year’s team, there were also current some of the team’s top fundraisers had a different reason to join team Sanford Burnham Prebys. Kim McKewon is a longtime donor to the Institute and has been participating in Padres Pedal the Cause since its inception in 2013. This year she raised more than $6,000; and to date, she has raised more than $30,000. 

“I pedal for my husband, Ray, who is in remission from leukemia because of science and research, the very focus of the grants that are given from the fundraising that comes out of this event,” she writes in her website bio.

It’s not too late to support Team Sanford Burnham Prebys
To date, team Sanford Burnham Prebys has raised more than $300,000 through Padres Pedal the Cause since its inception in 2013. And while this year’s ride is over, there is always time to support local cancer research. The fundraising deadline for this year’s Padre’s Pedal the Cause is April 18, and 100% of every dollar raised goes toward lifesaving cancer research. Help team Sanford Burnham Prebys create a world without cancer.

 

Support Team Sanford Burnham Prebys

 

 

Institute News

Sanford Burnham Prebys researchers awarded Curebound grants

AuthorMiles Martin
Date

March 20, 2023

Aninyda Bagchi, PhD, Linda Bradley, Lukas Chavez, PhD, Nicholas Cosford, PhD, and Michael Jackson, PhD

Each year, Sanford Burnham Prebys joins Padres Pedal the Cause, an annual fundraising event that raises money for Curebound which awards collaborative cancer grants in the San Diego area.

These grants include Discovery Grants, which provide seed funds for high-risk/high-reward research in the earliest phases, and Targeted Grants, which are larger awards ($500K) that help translate promising discoveries into treatments for the clinic.

In the 2022-2023 Curebound Research portfolio, five researchers from Sanford Burnham Prebys were awarded grants: Associate Professor Anindya Bagchi, PhD, Professor Linda Bradley, PhD, Assistant Professor Lukas Chavez, PhD, Professor Nicholas Cosford, PhD, and Professor Michael Jackson, PhD

2022 Discovery Grant: Treating incurable pediatric brain tumors 
Bagchi and Chavez will collaborate to advance a new therapeutic approach for medulloblastoma, the most common childhood brain tumor. They will be focusing on a gene called MYC, found only in the deadliest forms of medulloblastoma. This form of brain cancer is currently untreatable, but Bagchi and Chavez recently discovered a molecule that can help control the activity of the MYC gene and potentially inhibit the growth of medulloblastoma tumors. The researcher holds promise to reveal a new treatment approach for this incurable cancer. 

The grant is titled “Decoding the Role of the Long Non-Coding RNA PVT1 in Medulloblastoma.”

2023 Targeted Grant: Discovering a new immunotherapy drug for melanoma
Bradley will be working with Soo Jin Park, MD, from UC San Diego Health to advance a new immunotherapy approach for malignant melanoma. Despite recent advances, this type of skin cancer still causes thousands of deaths in the U.S. each year. The goal of their project is to develop a new drug for melanoma that can reactivate the tumor-killing properties of the patient’s own immune system. This therapeutic approach has the potential to destroy tumors that are resistant to existing therapies, which could help save lives.

The grant is titled, “Advancing Immune Checkpoint Inhibition of PSGL-1 for Treatment of Malignant Melanoma.
 

2022 Discovery Grant: Developing drugs for bone-metastatic prostate cancer
Cosford will work with Christina Jamieson, PhD, from the University of California, San Diego, to advance a new treatment approach for prostate cancer that has spread to the bones. Bone is the most common place for prostate cancer to metastasize, and this form of cancer is currently incurable. The researchers will look for drugs that can kill tumor cells by inhibiting autophagy, a process that promotes tumor progression. The results of the study could identify a new drug ready for clinical trials.

The grant is titled “Pre-Clinical Development of New Autophagy Targeting Drugs for Bone Metastatic Prostate Cancer.”

2022 Discovery Grant: Repurposing drugs for deadly childhood brain cancer
Jackson and Chavez will collaborate to identify new treatment options for ependymoma, an aggressive pediatric brain tumor and leading cause of death among childhood cancer patients. The researchers will screen patient tumor cells against drugs already approved by the FDA for other conditions, looking for drugs that could be repurposed to fight these tumors. Because FDA-approved drugs are known to be safe for humans, this may prove to be the quickest way to help patients currently living with this cancer. 

The grant is titled “High Throughput-Screen for Inhibitors of Pediatric Ependymoma.”

Institute News

Sanford Burnham Prebys celebrates one of its legends

AuthorMiles Martin
Date

March 8, 2023

Erkki Ruoslahti, MD, PhD

In 2022, Distinguished Professor Emeritus Erkki Ruoslahti, MD, PhD, was awarded the Albert Lasker Basic Medical Research Award, the top American prize for biomedical research. Ruoslahti was also among the first scientists to join the Institute in the late 1970s, where he completed this award-winning research. To celebrate Ruoslahti’s career and accomplishments, Sanford Burnham Prebys hosted a special lecture with the esteemed scientist as well as a celebratory reception afterward.

“Erkki’s illustrious career is one that keeps us all inspired—me, especially, as I follow in his footsteps in leading this Institute,” says David A. Brenner, MD, president and CEO of Sanford Burnham Prebys. “His Lasker Award win is so very much deserved. Not only does it recognize his outstanding influence in the field, but it also elevates the status of our Institute in the research community.”

Erkki Ruoslahti gives lecture to full a full auditorium

Ruoslahti, who shares the award with Richard O. Hynes from the Massachusetts Institute of Technology, and Timothy A. Springer from Boston Children’s Hospital and Harvard Medical School, began his presentation with the research that led to his discovery of the integrins—proteins found on the surface of cells that helps them attach to, and communicate with, nearby cells and the extracellular matrix. 

Ruoslahti’s road to the discovery of integrins began at the University of Helsinki, where, along with his colleagues, he discovered fibronectin, a protein that helps surround, support and give structure to cells and tissues in the body. However, the biggest breakthroughs were yet to come.

“My research on fibronectin and the subsequent discovery of the integrins really got going in my first years at Sanford Burnham Prebys,” says Ruoslahti, who first joined the Institute in 1979, when it was known as the La Jolla Cancer Research Foundation.

The Ruoslahti research team discovered that a simple sequence of three amino acids, called RGD, within fibronectin, attaches directly to cells. They were then able to synthesize RGD and use it as a tool to discover the cell-surface receptors today known as the integrins. This seemingly small discovery created an entirely new subdiscipline of molecular biology.

“The Lasker Award is given for a fundamental discovery that opens up a new area of biomedical science. It is America’s top biomedical research award and is often referred to as ‘America’s Nobel,’” says Brenner. “This is a profound honor, one that is only given to those who have made the greatest impact in our field.”

In 1989, Ruoslahti became president and CEO of the Institute, a position he held until returning to full-time research in 2002. He became a Distinguished Professor Emeritus at Sanford Burnham Prebys in 2020. Ruoslahti has previously received the Japan Prize, the Gairdner Foundation International Award, the G.H.A. Clowes Memorial Award, and the Robert J. and Claire Pasarow Foundation Medical Research Award. He is also a Knight of the Order of the White Rose of Finland, a Commander of the Order of the Lion of Finland and is among the most cited scientists in the world.

Institute News

Is cloud computing a game changer in cancer research? Three big questions for Lukas Chavez

AuthorMiles Martin
Date

February 22, 2023

Lukas Chavez, PhD

As an assistant professor at Sanford Burnham Prebys and director of the Neuro-Oncology Molecular Tumor Board at Rady Children’s Hospital, Lukas Chavez, PhD, leverages modern technology for precision diagnostics and for uncovering new treatment options for the most aggressive childhood brain cancers.

We spoke to Chavez about his work and asked him how modern technology—particularly cloud computing—is shifting the approach to cancer research.

How are you using new technologies to advance your research?

New technologies are helping us generate a huge amount of data as well as many new types of data. All this new information at our disposal has created a pressing need for tools to make sense of it and maximize their benefits. That’s where computational biology and bioinformatics come into play. The childhood brain cancers I work on are very rare, which has historically made it difficult to study large numbers of cases and identify patterns.

Now, data for thousands of cases can be stored in the cloud. By creating data analysis tools, we can reveal insights that we would never have seen otherwise. For example, we’ve developed tools that can use patient data in the cloud to categorize brain cancers into subtypes we’ve never identified before, and we’re learning that there are many more types of brain tumors than we’ve previously understood. We’re basically transforming the classic histo-pathological approach that people have studied for decades by looking at tumor tissues under the microscope and turning that into data science.

How is cloud computing improving cancer research in general?

Assembling big datasets delays everything, so I believe the main idea of cloud computing is really to store data in the cloud, then bring the computational tools to the data, not the other way around.

My team did one study where we assembled publicly available data, and basically downloaded everything locally. The data assembly process alone took at least two to three years because of all the data access agreements and legal offices that were involved.

And that is the burden that cloud computing infrastructures remove. All of this personalized cancer data can be centrally stored in the cloud, which makes it available to more researchers while keeping it secure to protect patient privacy. Researchers can get access without downloading the data, so they are not responsible for data protection anymore. It’s both faster and more secure to just bring your tools to the data.

Are there any risks we need to be aware of?

Like any new technology, we need to be clear about how we use it. The technology is another tool in the toolbox of patient care. It will never entirely replace physicians and researchers, but it can complement and assist them.

Also, because we use costly and sophisticated tools that are being built and trained on very specific patient groups, we need to be careful that these tools are not only helping wealthier segments of society. Ideally, these tools will be expanded worldwide to help everybody affected by cancer.

Institute News

Tight employment a sign of resilience: Interview with David Brenner

AuthorMiles Martin
Date

February 9, 2023

David A Brenner, MD

Sanford Burnham Prebys recently received a substantial gift from namesake benefactor T. Denny Sanford, specifically to hire 20 new faculty positions in research areas including cancer, neurodegeneration and computational biology.

For president and CEO David A. Brenner, MD, the gift provides the opportunity to bring the very best and brightest to the Institute. It is also a sign of how resilient and successful the biomedical research sector is in the San Diego region.

“Our goal is to recruit the smartest, most innovative scientists from the best laboratories in the top institutions in the world,” said, David Brenner. “In addition, this new gift will be used to invest in our current faculty and research infrastructure.”

The success of life science as an industry has made finding talented researchers harder over the years. According to a report published by CBRE, the number of researchers working in life sciences grew 79% from 2001 to 2021. Yet despite that growth, life science occupations had the second-lowest unemployment rate of all U.S. occupations at just 0.6%.

“There is an incredible demand for researchers and scientists, and shortage of biomedical skilled labor in general. This tight labor market and competition for talent is linked to the success of institutes and need for world-class scientists,” Brenner said, adding that to help meet the demand, Sanford Burnham Prebys doubled the size of its entering class of its graduate school this year.

Research institutes like Sanford Burnham Prebys compete against for-profit private and public companies for talented graduates to come work for them, which is why philanthropic donations like the one from Sanford are important to nonprofit research enterprises.

“If you look at how nonprofit biomedical research institutions get support, there are not as many avenues for funding. Competitive grants do not provide project startup funds,” Brenner said. “T. Denny Sanford’s recent gift will allow Sanford Burnham Prebys to attract the most promising scientists from around the world and support them as they develop into world-class scientists. In addition, the donation will allow Sanford Burnham Prebys to invest in our research infrastructure and technology, imperative when recruiting the brightest minds in biomedical research.”

This story was adapted from a special report in the San Diego Business Journal. 

Institute News

Three big questions for cutting-edge biologist Will Wang

AuthorMiles Martin
Date

January 26, 2023

Will Wang, PhD

Will Wang’s spatial omics approach to studying neuromuscular diseases is unique.

He works at the intersection of biology and computer science to study how complex systems of cells interact, specifically focusing on the connections between nerves, muscles, and the immune response and their role in neuromuscular diseases.

We sat down with Wang, who recently joined the Institute as an assistant professor, to discuss his work and how computer technology is shaping the landscape of biomedical research.

How is your team taking advantage of computer technology to study neuromuscular diseases?

No cell exists in isolation. All our cells are organized into complex tissues with different types of cells interacting with each other. We study what happens at these points of interaction, such as where nerves connect to muscle cells. Combining many different types of data such as single cell sequencing, spatial proteomics, and measures of cell-cell signaling helps us get a more holistic look at how interactions between cells determine tissue function, as well as how these interactions are disrupted in injury and disease. Artificial neural networks help us make sense of these different types of data by finding patterns and insights the human brain can’t see on its own. And because computers can learn from the vast modality of data that we gather, we can also use them to help predict how biological systems will behave in the lab. The process goes both ways – from biology to computers and from computers to biology. 

How will these technologies shape the future of biomedical research?

Biology and computer programming are two different languages. There are a lot of mathematicians and programmers who are great at coming up with solutions to process data, but biological questions can get lost in translation and it’s easy to miss the bigger picture. And pure biologists don’t necessarily understand the full scope of what computers can do for them. If we’re going to get the most out of this technology in biomedical research, we need people with enough expertise in both areas that they can bridge the gap, which is what our lab is trying to do. Over time we’re going to see more and more labs that combine traditional biological experiments and data analysis approaches with artificial intelligence and machine learning. 

Are there any potential risks to these new technologies?

Artifical intelligence is here to accelerate discovery. Mundane tasks and measurements that took me weeks to carry out as a graduate student can be automated to a matter of minutes. We can now find patterns in high dimensional images that the human brain can’t easily visualize. However, any kind of artificial intelligence comes with a certain amount of risk if people don’t understand when and how to use the tools. If you just take the absolute word of the algorithm, there will inevitably be times where it’s not correct. As scientists, we use artificial intelligence as a cutting-edge discovery tool, but need to validate the findings in terms of the biology. At the end of the day, it is us, scientists, who are here to drive the discovery process and design real life experiments to make sure our therapies are safe and efficacious. 

Institute News

STEM Shadow Day gives diverse students an inside look at Sanford Burnham Prebys

AuthorMiles Martin
Date

December 2, 2022

Michael Jackson, PhD, explaining the Institute's drug discovery research at the Prebys Center

As part of ongoing efforts to increase the diversity of the Institute’s trainees, Sanford Burnham Prebys’ DEI Education & Training Committee hosted 36 high school and college students from historically underrepresented backgrounds for a day of lab tours and workshops. The event was sponsored by the San Diego MESA alliance, and more than 20 faculty, staff and current trainees came together to help make the event possible. 

“It’s critical for all students to have opportunities to learn more about scientific research at an early phase in their academic career,” says Paula Checchi, PhD, an administrator in the Institute’s Office of Education, Training and International Students and a leader of our Education & Training Diversity, Equity and Inclusion Committee. “Diversity in the lab contributes so much, both to the trainees’ success and to the overall progress of biomedical research. If we’re going to create a more diverse research community, we need to work from the ground up and support young scholars from all backgrounds every step of the way.”

The day began with an introduction by Hudson Freeze, PhD and a keynote address from Alessandra Sacco, PhD, who spoke to the challenges she’s faced as an Italian American and as a woman in science. 

“My parents When I was younger, some of my relatives asked me why I even wanted to study this because the role of women in science was very different then,” Sacco said. “When I started, I was the only woman in the lab, and that made it difficult to integrate. I didn’t think I’d last a week, but day by day you learn to overcome those challenges in front of you, and it gets a little easier, and it becomes an exciting opportunity to grow.”

She also spoke to the importance of diversity in STEM.

“Diversity is a huge resource, especially in scientific research,” Sacco said. “If you’re asking questions nobody has the answer to, and everybody in the room is from the same background with the same mindset, you’re less likely to less likely to find creative answers. Diversity enriches the scientific discussion, and we’re all part of the same research community.”

After the opening comments, high school students attended workshops on networking skills and mentorship. Meanwhile, college students divided into groups and went on guided tours of labs across campus, where they saw firsthand how Sanford Burnham Prebys researchers are solving pressing problems in medicine.

“It’s so exciting that researchers like Dr. Haricharan are looking at breast cancer in Black and brown women and really getting down to the fundamental biology, not just focusing on socioeconomic factors,” says Shadow Day participant Serina Cuza, referring to recent research from the lab of Svasti Haricharan, PhD “I know there could be pushback, but that’s how you know the research is potentially a breakthrough.”

The event ended with a networking lunch followed by a poster session, featuring work by students in the Sanford Burnham Prebys Graduate School of Biomedical Sciences and alumni of this summer’s SPARK internship program.

“I really enjoyed all the people that I met today,” said Shadow Day participant Yaritza Rubio. “I like that there are so many people from so many different parts of the world here.”